Skip to Content

'
Roeland GW Verhaak, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1410
Houston, TX 77030
Room Number: FCT4.5010
Phone: 713-563-2293
Fax: 713-563-4242
Email: rverhaak@mdanderson.org

Education & Training

Degree-Granting Education

2006 Erasmus University Medical Center, Rotterdam, Netherlands, PHD, Medicine
2000 Radboud University, Nijmegen, Netherlands, MSc, Biomedical Science and Computer Science

Postgraduate Training

3/2007-1/2010 Research Fellowship, Broad Institute of Harvard and MIT, Cambridge, MA, Matthew Meyerson

Experience/Service

Academic Appointments

Computational Biologist, The Broad Institute of MIT and Harvard, Cambridge, MA, 2/2010-9/2010
Research Scientist, Hematology, Erasmus Medical Center, Rotterdam, Netherlands, 6/2006-1/2007
Visiting Scientist, Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA, 3/2006-5/2006

Administrative Appointments/Responsibilities

Postdoctoral Fellow, Dana Farber Cancer Institute / the Broad Institute of MIT and Harvard, Cambridge, MA, 4/2007-1/2010
PhD Student, Medical Informatics, Radboud University, Nijmegen, Netherlands, 10/2000-3/2002

Other Appointments/Responsibilities

Software Engineer, Dalicon BV, Nijmegen, Netherlands, 4/2002-3/2003

Honors and Awards

2008-2010 Fundamental and pre-clinical fellowship, Dutch Cancer Society KWF
2006 Netherlands Genomics Initiative Fellowship

Selected Publications

Peer-Reviewed Original Research Articles
1. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. e-Pub 12/21/2012. PMID: 23257362.
2. Verhaak RG, Mills GB. Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Res 14(5). e-Pub 10/29/2012. PMID: 23106814.
3. Zong H, Verhaak RG, Canolk P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn 12(4):383-94, 5/2012. PMCID: PMC3368274.
4. Zheng S, Chheda MG, Verhaak RG. Studying a complex tumor: potential and pitfalls. Cancer J 18(1):107-14, 1/2012. PMID: 22290264.
5. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, Zong H. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146(2):209-21, 7/2011. e-Pub 7/2011. PMCID: PMC3143261.
6. The Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. Nature 474(7353):609-15, 6/2011.
7. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. Suppression of Lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-4, 5/2011. e-Pub 4/2011. PMCID: PMC3088778.
8. Wang XV, Verhaak RG, Purdom E, Spellman PT, Speed TP. Unifying gene expression measures from multiple platforms using factor analysis. PLoS One 6(3):e17691, 2011. e-Pub 3/2011. PMCID: PMC3059153.
9. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510-22, 5/2010. e-Pub 4/2010. PMCID: PMC2872684.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110, 1/2010. PMCID: PMC2818769.
11. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94(1):131-4, 1/2009. e-Pub 10/2008. PMCID: PMC2625407.
12. The Cancer Genome Atlas Research Network (Verhaak included). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-8, 10/2008.
13. Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, Libermann TA, Delwel R, Tenen DG. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 38(11):1269-77, 11/2006. e-Pub 10/2006. PMID: 17041602.
14. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106(12):3747-54, 12/2005. e-Pub 8/2005. PMID: 16109776.
15. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617-28, 4/2004. PMID: 15084694.

Grant & Contract Support

Title: Identify signature profile for sensitivity /resistance to P13K pathway inhibitors to predict response to therapy in glioblastoma.
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: W.K. Alfred Yung
Duration: 12/1/2011 - 11/30/2014
 
Title: Identification of Intragenic Breakpoints in Glioblastoma Multiforme (Brain Cancer SPORE Career Development Award, PP-CDP 4)
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2011 - 8/31/2013
 
Title: Validating Intragenic Breakpoints in Ovarian Cancer (Ovarian cancer SPORE Career Development Award)
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2011 - 8/31/2013
 
Title: Advancing Staging & Prognosis in Early-Stage Melanoma
Funding Source: Melanoma Research Alliance
Role: Investigator
Principal Investigator: Jeffrey Gershenwald
Duration: 8/1/2011 - 7/31/2014
 
Title: Integrative Pipeline for Analysis and Translational Application of TCGA Data (GDAC): Carry-Forward Funds
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: John Weinstein
Duration: 9/29/2009 - 7/31/2014
 
Title: An Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: John N. Weinstein
Duration: 9/29/2009 - 7/31/2014
 
Title: ARRA: Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC) - Admin. Supplement
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: John Weinstein
Duration: 9/29/2009 - 11/30/2012

Last updated: 2/5/2013